CliffBio
small molecule

XELJANZ XR

TOFACITINIB CITRATE

Loss of exclusivitySeptember 2034latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameXELJANZ XR
Active ingredientTOFACITINIB CITRATE
StrengthEQ 22MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusRX

Listed patents

PatentExpiresType
10639309*PEDSeptember 2034—
11253523*PEDSeptember 2034—
11253523March 2034use U-3329
10639309March 2034product
RE41783*PEDJune 2026—
RE41783December 2025substance

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found